Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 562Carcinoma, Non-Small-Cell Lung 482Ovarian Neoplasms 326Lung Neoplasms 203Fallopian Tube Neoplasms 152Neoplasms 150Triple Negative Breast Neoplasms 125Esophageal Neoplasms 125Stomach Neoplasms 121Neoplasm Metastasis 119Carcinoma, Ovarian Epithelial 114Endometrial Neoplasms 95Squamous Cell Carcinoma of Head and Neck 94Uterine Cervical Neoplasms 79Head and Neck Neoplasms 77Esophageal Squamous Cell Carcinoma 77Recurrence 48Adenocarcinoma of Lung 47Parkinson Disease 4, Autosomal Dominant Lewy Body 45Melanoma 42Carcinoma 42Urinary Bladder Neoplasms 41Adenocarcinoma Of Esophagus 36Small Cell Lung Carcinoma 35Carcinoma, Squamous Cell 34Prostatic Neoplasms 31Pancreatic Neoplasms 29Breast Neoplasms, Male 28Unspecified Adult Solid Tumor, Protocol Specific 27Colorectal Neoplasms 25

Interventions

Trastuzumab 1Paclitaxel 1MM-111 1Lapatinib 1Docetaxel 1Cisplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × HER-2 Gene Amplification × Paclitaxel × Clear all
NCT01304784 2015-12-16

A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive Cancer

Merrimack Pharmaceuticals

Phase 1 Completed
100 enrolled

HER-2 Gene Amplification

Data powered by HemOnc (CC BY 4.0) Colophon âš¡